Amivantamab Regimen Boosts Survival in EGFR+ NSCLC Subtype

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated diseaseConsistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomesASCO 2026 results reinforce the significance…

Amivantamab Regimen Boosts Survival in EGFR+ NSCLC Subtype

Data from the phase 1/1b CHRYSALIS-2 trial show enduring responses with amivantamab plus lazertinib in this EGFR-mutated NSCLC population.